Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.
Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.
Vir Biotechnology announced that Dr. Phil Pang, its Chief Medical Officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 12:00 p.m. PT / 3:00 p.m. ET.
Investors can access a live webcast of the presentation in the Investors section of the Vir website, which will also be archived for 30 days.
Vir Biotechnology is dedicated to treating and preventing serious infectious diseases by leveraging innovative technologies and immunologic insights. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology announced that Phil Pang, M.D., Ph.D., Executive Vice President and Chief Medical Officer, will present at the Barclays Global Healthcare Conference on March 15, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of this presentation will be available on their website under the Events & Presentations section and archived for 30 days.
Vir Biotechnology is a commercial-stage immunology company focused on treating and preventing serious infectious diseases through innovative technology platforms. Their pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology has announced that Bolyn Hubby, Ph.D., the Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel about infectious diseases at the Cowen 43rd Annual Health Care Conference. This event is scheduled for March 7, 2023, at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast of the panel will be available on the Vir website under the Events & Presentations section and will remain accessible for 30 days.
Vir Biotechnology focuses on innovative solutions to treat serious infectious diseases through advanced immunological technologies. Its development pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology reported a significant year in 2022, recognizing $1.5 billion in collaboration revenue from sotrovimab. The company has a robust financial position with approximately $2.4 billion in cash and investments, allowing it to fund ongoing clinical trials in hepatitis B, hepatitis D, and influenza. Notable leadership transitions were announced, including the retirement of CEO George Scangos, effective April 3, 2023, and the appointment of Marianne De Backer as his successor. The company anticipates critical Phase 2 trial data and continues to progress in addressing COVID-19 and other infectious diseases.
Vir Biotechnology announced positive final draft guidance from the UK's NICE recommending the use of sotrovimab, a monoclonal antibody for COVID-19 treatment in adults at increased risk for severe disease.
This recommendation applies to patients who do not require supplemental oxygen and where alternatives like nirmatrelvir/ritonavir (Paxlovid) are unsuitable. Despite the positive guidance, no significant additional sales of sotrovimab in the UK are expected in 2023 due to existing inventory. Sotrovimab has received authorizations in over 40 countries but is not approved in the US.
Vir Biotechnology, a commercial-stage immunology company, announced it will provide a corporate update and report financial results for Q4 and full year 2022 on February 23, 2023. The financial results will be accessible via a press release after market close and can be found in the Investors section of their website.
Vir focuses on serious infectious diseases utilizing advanced immunologic technologies. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology has appointed Sung Lee as its new Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. He takes over from Howard Horn, who will remain in an advisory role during the transition. Lee brings over 20 years of experience in financial leadership, having held senior positions at companies like Gilead Sciences and most recently served as CFO at MorphoSys AG.
The company's CEO, George Scangos, expressed confidence in Lee’s ability to drive growth and strengthen financial performance. Horn, a key figure in Vir's early development, highlighted the company's strong financial foundation as he departs.
Vir Biotechnology announced an amendment to its collaboration agreement with GSK, allowing Vir to independently advance next-generation COVID-19 solutions and other respiratory therapies.
The companies will continue their partnership on sotrovimab and develop additional treatments for influenza. Sotrovimab, an investigational monoclonal antibody, is designed for optimal lung concentration but is not authorized in the US.
Vir retains rights to future developments from the collaboration while paying royalties to GSK. CEO George Scangos emphasized Vir's commitment to addressing urgent patient needs.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced the retirement of CEO George Scangos, effective April 3, 2023, transitioning to an advisory role until June 2, 2023. Marianne De Backer succeeds him, bringing over two decades of leadership experience, including roles at Bayer and Johnson & Johnson. Under Scangos, Vir developed life-saving therapies for Ebola and COVID-19, boasting a pipeline across five therapeutic areas and approximately $2.7 billion in cash. The Board expresses confidence in De Backer’s ability to drive future growth, leveraging her strategic expertise and operational successes.
Vir Biotechnology (Nasdaq: VIR) anticipates critical Phase 2 readouts in 2023 for its advanced programs targeting hepatitis B, hepatitis D, and influenza. CEO George Scangos will discuss the company's 2023 catalysts and long-term strategies at the upcoming J.P. Morgan Healthcare Conference on January 10. Vir maintains a strong balance sheet, enabling it to fund its robust portfolio and explore external opportunities. The company focuses on immunology to treat serious infectious diseases, leveraging four technology platforms for drug development.
